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Abstract  
Sickle Cell Disease (SCD) is an inherited blood disorder that affects many African Americans 
globally. This disease is characterized by acute complications from chronic anemia, episodes of 
painful acute on chronic vaso-occlusive pain syndrome, and organ damage. Despite optimizing 
Hydroxyurea (HU), these events can still occur. The purpose of the DNP project was to 
implement an algorithm to standardize HU for specific genotypes, particularly hemoglobin SS 
and hemoglobin Sβ-0-thalassemia. The project aimed to increase HU prescribing and improve 
educational opportunities for this disease-modifying therapy to achieve the benchmark of at least 
80% prescribing. The Plan-Do-Study-Act methodology was used to test change and evaluate HU 
prescribing. Findings from the project indicated an increase in prescribing with the use of the 
algorithm. The algorithm provided an evidence-based guideline for decision-making based on 
eligible hemoglobinopathies. Standardizing this algorithm enabled providers to increase HU 
prescribing and provide educational leaflets on HU to patients which, in turn, increased the 
interests of the participants to engage in self-management. HU is an effective way of improving 
the patients’ outcomes for preventing complications with SCD.  
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Section I. Introduction 
Background 
 Sickle Cell Disease (SCD) represents a blood disease inherited from an autosomal 
recessive pattern (Keikhaei et al., 2015). According to the author, compared to healthy 
individuals, patients with SCD experienced significant declines in their health-related quality of 
life (HRQOL) across their life span due to the disease and its complications.  Badawy et al. 
(2017) indicate that SCD is an inherited red blood cell disorder seen in 100,000 African 
Americans, namely in 1 out every 365 births. The disease is characterized by “chronic anemia, 
painful crises, organ damage, reduced quality of life (QOL), high health care costs, and 
shortened life span” (Smaldone et al., 2016, p. 2).  
When addressing SCD, particular attention should be paid to Hydroxyurea (HU), a 
disease-modifying medication recognized as a standard of care used to prevent symptomatology 
in patients with SCD. This medicine is beneficial in both adults and children with decreasing the 
symptomologies and clinical manifestations of the disease. Hydroxyurea is an oral medication 
that is dosed once daily. The only approved therapeutic drug for sickle cell disease is noted to 
reduce symptoms, morbidity, and mortality and improve the individual’s quality of life 
(Smaldone et al., 2016).  
The Food and Drug Administration approves this medication for treating SCD. 
Hydroxyurea therapy emerged as a treatment for SCD that has evolved over thirty years ago, 
which benefits have been shown by increasing the fetal hemoglobin concentrations in adults with 
sickle cell disease (Smith et al., 2019). HU has several clinical benefits associated with 
decreasing vaso-occlusive sickle cell pain crises, decreasing acute chest syndrome, preserving 
organ function, and preventing organ damage to target organs such as the liver, heart, brain, and  
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kidneys. HU is an efficacious disease-modifying medication that is widely available and can be 
inexpensive. Ware (2015) noted that “the National Heart Lung and Blood Institute (NHLBI) 
issued evidence-based guidelines for SCD with an entire chapter devoted to HU therapy” (p. 
436). 
Organizational Needs Statement  
The Hematology Adult Comprehensive Sickle Cell Clinic, affiliated with a nonprofit 
healthcare system in central North Carolina, has identified the need to improve HU prescribing 
in specific genotypes. The clinic will be proposing an algorithm for standardizing HU in specific 
genotypes, particularly hemoglobin SS and hemoglobin Sβ-0-thalassemia. The clinic will partner 
with several organizations initiating a quality improvement project for HU. Other organizations 
will propose their quality improvement (QI) initiative for HU by providing feedback for HU 
adherence. The partnering organization will connect with namely the Education and Mentoring 
to Bring Access to Care (EMBRACE) SCD Network to provide the best resources for patients 
with sickle cell disease. The partnership includes investigators from eight other states in 
Southeastern USA, with clinics implementing standards of care to improve HU prescribing. 
Institutions will collaborate in sharing individualized plans with clinicians in ways to improve 
HU prescribing using evidence-based guidelines.  
EMBRACE is a collaborative network committed to increasing the number of providers 
adhering to the National, Heart, Lung, and Blood Institute (NHLBI) guidelines for providing 
exceptional care to patients with sickle cell disease, initiatives for increasing the pool of 
providers offering grounded evidence-based SCD care by disseminating technology to support 
providers, and implementing strategies for improving access to quality care in patients with SCD 
in a medical home. [Regional Project Manager] EMBRACE Project-Sickle Cell Disease, 
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personal communication, July 17, 2020). The proposed DNP project will be a quality initiative in 
collaboration with EMBRACE to implement an algorithm in the clinic to standardize the use of 
HU. The benchmark for the clinic is to achieve the goal of prescribing HU at least 80% or more 
significantly in the adult population with specific genotypes [project champion], personal 
communication, May 29, 2020). This effort would substantially prevent morbidity, mortality, and 
improve the quality of life of patients with SCD.  
Currently, the clinic serves approximately 450 SCD adult patients, with at least two-
thirds of the patients with genotypes of hemoglobin SS and hemoglobin Sβ-0-thalassemia 
[Associate Professor of Adult Comprehensive Sickle Cell Clinic] personal communication, July 
6, 2020). A recent chart audit indicated the providers were prescribing HU at 60% [Associate 
Professor] of Adult Comprehensive Sickle Cell Clinic personal communication, July 6, 2020). In 
collaboration with the eight states, the organization recognizes the importance of this initiative 
for improving hydroxyurea prescribing by establishing measurable goals for improving the 
communities’ healthcare in patients with SCD. The goal is to implement a standardized 
algorithm for HU prescribing of specific genotypes that include educating the staff, patient, 
family, and multidisciplinary clinicians about HU.  
Presently, the clinic has not achieved the benchmark of at least 80% of eligible patients 
receiving HU prescriptions. A process to identify patients who meet the criteria to receive HU 
will be essential for improving the care of patients with SCD. This allows providers and 
clinicians the opportunity to discuss HU with specific patients of identified genotypes. 
According to Ware (2015), the NHLBI’s first treatment recommendation, based on the consensus 
panel of expertise, includes educating all patients and families about HU therapy.  
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 According to Healthy People (HP) 2020, major objectives include “increasing the 
proportion of persons with hemoglobinopathies who receive early continuous screening for 
complications, increases the proportion of persons with a diagnosis of hemoglobinopathies who 
receive disease-modifying therapies, and increase the proportion of community-based 
organizations that provide outreach and awareness campaigns for hemoglobinopathies” (Office 
of Disease and Health Promotion, 2015, para.4). The Healthy People 2030 proposed “a leading 
health indicator to increase the proportion of Medicare beneficiaries with SCD who receive 
disease-modifying therapies” (Office of Disease and Health Promotion, 2018, para. 4). The 
indicators will help educate the community, patients, and staff concerning the clinical benefits of 
HU prescribing. This supports the initiative to implement an algorithm with standardizing HU in 
practice. The indicators align with the clinic’s goals to increase prescribing and achieving the 
benchmark of 80%.  
Swarthout and Bishop (2017) noted that a recently developed framework aimed to 
improve health system performance deserves careful regard. From their perspective, the Triple 
Aim framework is likely “to improve health-systems performance by focusing on improving the 
individual patient experience, improving health outcomes for populations of patients, and 
reducing per capita cost of healthcare” (p. 1405). The need for this project aligns with the Triple 
Aim by initiating an algorithm that provides guidelines for standardizing HU prescribing that 
includes quality of care, improves patients’ outcomes, and experiences of SCD. In addition, the 
use of HU decreases clinical manifestations of SCD by reducing the capital costs of care related 
to admissions or readmissions.  
Problem Statement  
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 Luzzatto and Makani (2019) noted that “HU is recognized in the national and international 
guidelines as the standard of care for patients with SCD” (p. 187).  HU is noted to decrease effects 
on pain reduction, prolong survival, improve quality of life, and prevent organ damage with 
preserving the quality of life of individuals with SCD. Currently, there is no standardized algorithm 
for prescribing HU for patients with SCD at the clinic. The current prescribing HU rate is 
approximately 60%, below the clinic goal of 80% [Associate Professor] of Adult Comprehensive 
Sickle Cell Clinic, personal communication, July 6, 2020). The projected measurable goal is that 
80% of adults with SCD of specified genotypes will receive HU [Project Champion] personal 
communication, May 29, 2020) 
Purpose Statement  
 The purpose of the proposed Doctor of Nursing Practice (DNP) project is to develop and 
implement an algorithm to standardize HU in the Hematology Adult Comprehensive Sickle Cell 
Clinic. In addition, this project will provide an opportunity to address any barriers to prescribing 
and evaluate strategies in achieving the benchmark of 80%. This will be a collaborative effort 
with the clinic partnering with EMBRACE in providing evidenced-based care for improving HU 
prescribing in SCD patients [Regional Project Manager] EMBRACE Project-Sickle Cell 
Disease, personal communication, July 17, 2020). 
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Section II: Evidence  
Literature Review 
 The literature review was conducted using the search engines, namely, Google Scholar, 
PubMed, and Cumulative Index to Nursing and Allied Health (CINAHL). The search terms used 
in Google Scholar included sickle cell disease, sickle cell anemia, adults, Hydroxyurea, 
medication adherence, hematological improvement, novel therapies, anemia, and 
hydroxycarbamide (another abbreviated name for HU). The MeSH terms used included the 
following ones: MH “Hydroxyurea”, OR TI (hydroxyurea), OR AB (hydroxyurea), 
“Hydroxyurea” (MeSH) OR hydroxyurea (tiab). The PubMed search yielded 49 articles, 
CINAHL 72, and Google scholar 31 articles. The articles were reviewed looking for sickle cell 
disease (SCD), hydroxyurea, and adult populations with SCD. Once the additional limitations of 
inclusion and exclusion criteria were applied, this narrowed the search significantly.  
Articles of interest, with publications dating from 1997-2020, were retrieved with 2 from 
Google Scholar, 12 from PubMed, and 6 from CINAHL (see Appendix A). The articles reviewed 
included the last five years, published and written in English. Literature were synthesized by 
using Melnyk & Fineout (2019) levels of evidence. The levels of evidence encompassed Levels 
VI and above (see Appendix B). The inclusion and eligibility criteria for the articles included 
persons aged 16 years or older, with sickle cell disease of specific genotypes hemoglobin SS and 
hemoglobin Sβ-0-thalassemia documented by the past medical history of hemoglobin 
electrophoresis, currently not on HU. The exclusion criteria included adults without a current 
diagnosis of SCD or those considered pediatric patients with SCD. Articles not meeting the 
inclusion criteria were removed from the literature of review. There were 16 articles retained. 
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Current State of Knowledge 
 The most recent published report provides a summary for improving the quality of care 
for individuals with SCD with evidence-based recommendations to guide practice for the 
treatment of adults with sickle cell disease (National Heart Lung and Blood Institute [NHLBI], 
2014). Green et al. (2017) state that offering HU, a sole FDA-approved treatment, is the standard 
of care for eligible patients with SCD. In addition, the author states that HU provides anti-
sickling properties that prevent the clinical manifestations that include vaso-occlusive crises and 
acute chest syndrome.  
According to Luzzatto and Makani (2019), HU is recognized in national and international 
guidelines as the standard of care in patients with SCD. HU is considered one of the novel 
therapies currently being used to treat SCD. HU has the efficacy for alleviation, prevention, or 
even reversal of chronic damage of organs and effects on long-term mortality in individuals with 
SCD (Smaldone et al., 2016). The author noted that HU and its clinical benefits are pointed out 
for improving laboratory parameters, reduce clinical complications, and improving survival 
rates. 
The American Society of Hematology strongly recommends HU for people with 
hemoglobin SS and hemoglobin Sβ-0-thalassemia. This treatment recommendation set high 
standards for specialists caring for patients with SCD. The literature review supported NHLBI 
guidelines of an algorithm as a guide for standardizing HU nationally in the specified genotypes.  
Current Approaches to Solving Improving Hydroxyurea Prescribing  
 There were several approaches for addressing HU prescribing in the clinic. According to 
Badawy et al. (2018) patient-centered eHealth interventions with telemedicine, e-chats, and 
mobile messages can be used to enhance patient-centered care with decision making. Improving 
patient engagement is one important outcome that eHealth interventions improved the patients’ 
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self-engagement in their healthcare. Interventions of eHealth were used in the clinic for 
discussing HU with patients by telemedicine since ideally, we reside in a world that utilizes 
technology regularly. This provided an intervention for reaching out to participants, of specific 
genotypes with education about HU (see Appendix C). The strategy incorporates text messaging, 
mobile APPs, and web-based apps. The interventions of web-based applications improved the 
patients’ knowledge about HU and provided feedback about the medication.  
 Hankins et al. (2020) asserted that Mobile health (mHealth) apps could potentially 
provide benefits for the increasing adherence to HU and facilitation of prescriptions among 
medical providers. The existing body of research notes that support for mHealth provides 
interventions for improving treatment adherence with various chronic diseases, including SCD. 
The author mentions that mHealth can aide physicians in decision-making and facilitate 
consultations with other providers and experts in their areas of expertise. This would serve as an 
intervention for the clinic to help optimize the HU prescribing of providers.  
The clinic used coaching from expert clinicians explaining the clinical benefits of HU 
with tracking prescribing of the providers. This strategy would inform the patients about HU and 
its clinical usefulness. According to Green et al. (2017) community healthcare workers are great 
adjunct staff for supporting the coordination of self-management responsibility to support 
participants’ daily habit of HU adherence. The self-management interventions could educate 
patients about HU and provide a direct connection for patients to follow up with using technical 
resources with messaging or emailing providers about their HU adherence. The eligible 
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Evidence to Support the Algorithm 
The evidence-based algorithm guided the team on decision-making regarding HU of 
eligible hemoglobinopathies with hemoglobin SS and hemoglobin Sβ-0-thalassemia (see 
Appendix D). Bakshi et al. (2017) discussed two approaches of disease-modifying therapies for 
SCD: either the collaborative approach (CO) or proponent approach (PA). The methods include: 
1) CO, which is characterized by the need to emphasize and discuss all possible options to ensure 
that the family is making informed decisions, and 2) PA, by advocating a pre-determined 
treatment plan providing the patients/families’ options which were characterized by determining 
the treatment plan providing patient/families’ options with convincing them to accept the 
treatment of choice. 
 An algorithm for HU prescribing served as a guide for initiating HU. Since HU is 
recognized by the NHLBI standards of care for SCD nationally, this medication will be offered to 
the specified genotypes during their clinic visits. Green et al. (2017) state “that achieving the 
personal best, which is the maximizing of HU to the maximum tolerated dose, is the ideal option 
if tolerated by patients” (p. 2). Ware (2015) noted that HU has proven efficacy in numerous clinical 
trials as a disease-modifying medication used in SCD. HU should be offered to prevent irreversible 
complications in SCD. The author reported that HU is not a cure, but it significantly reduces the 
mortality of sickle cell anemia (SCA). The algorithm will be the intervention used in the clinic to 
initiate HU prescribing and education for eligible patients.  
The algorithm will be used for dose escalation to guide clinicians in meeting the maximum 
tolerated dose of HU prescribing. This initiative will introduce HU safely and effectively in 
genotypes at risk for severe irreversible complications of SCD. Strouse (2016) noted that 
hydroxyurea reduced hospital admissions, acute visits for pain, and acute chest syndrome by half 
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in randomized clinical trials. The author suggests that multiple observational studies demonstrated 
improved morbidity and mortality in children and adults with sickle cell anemia of hemoglobin SS 
and hemoglobin Sβ-0-thalassemia genotypes treated with HU. The best intervention would be 
establishing an algorithm for HU (see Appendix D). 
Evidenced-Based Practice Framework  
Theoretical Framework 
The Transtheoretical Model (TTM) has been identified as the theoretical framework in 
guiding this project. The stages of change theory within the TTM include: 1) pre-contemplation, 
2) contemplation, 3) preparation, 4) action, and 5) maintenance (Raihan & Cogburn, 2020). The 
pre-contemplation is the first stage of identifying a need for the protocol and awareness of HU 
prescribing. Contemplation is an awareness of the clinic not meeting the benchmark of at least 
80%. Preparation is identifying the problem and developing steps towards implementing a 
protocol with guidelines for HU. This is where change will occur. Finally, the maintenance step 
includes an ongoing implementation and evaluation of the algorithm for 12 weeks to determine if 
HU prescribing increases amongst the clinicians.  
According to Prochaska and Velicer (1997), the transtheoretical model gravitates towards 
the stages of change to integrate processes and principles of evolution from different intervention 
theories. The preconception is thinking about HU and the clinical benefits of prescribing to the 
specific genotypes. Contemplation is the stage in which the clinicians are aware of the benefits of 
HU prescribing and intending on implementing the algorithm in the next 12 weeks. The 
preparation stage is when providers are ready for prescribing hydroxyurea  
 with a plan of action to increase their monthly prescribing in individuals with specified 
genotypes of hemoglobin SS and hemoglobin Sβ-0-thalassemia. Finally, the maintenance phase 
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would be evaluating the sustainability of prescribing hydroxyurea of clinicians over a period. 
This will ensure that there’s no relapse in prescribing.  
Operational Framework 
The Plan, Do, Study, Act (PDSA) cycle, was the operational framework used to test, 
change, and evaluate the process of improvement with HU. According to Knudsen et al. (2019), 
the PDSA cycles are widely used for quality improvement (QI) strategies in various healthcare 
systems. The PDSA cycles was a continuum of three cycles during the implementation phase. 
The PDSA served as the cornerstone predictor to guide the steps of the project, and adjustment 
were integrated at each cycle. The prediction was that using the HU algorithm to standardize HU 
prescribing in clinical practices would increase HU prescriptions in the clinic. The project aimed 
to show the impact of using an algorithm for prescribing HU that is noted to prevent severe 
irreversible complications in SCD. The act was initiation the algorithm to improve HU 
prescribing. The operational framework was used for the QI project to implement change.   
Plan. Data was collected using clinical notes, snapshots, and laboratory assays of the 
eligible participants at the clinic. The project’s objective were to determine if providing an 
algorithm to providers and educational leaflets improved HU prescribing. The project lead 
collaborated with the team members about the process for implementing the projects’ PDSA 
Cycles 1, 2, and 3.  
Do. This stage of implementation was the testing of the algorithm, initially in the first 
cycle to be followed additionally by the subsequent second, and third cycles, noticing the effects 
of HU prescribing of the providers in the setting of the COVID-19 pandemic.  
This encompasses plotting the data weekly on the spreadsheets. Additionally, the activity of 
plotting data on the run chart to track the changes in weekly prescribing.  
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Study. Data analysis was collected and analyzed over 12 weeks. The initial goal was to 
reach the 80% or more benchmark for HU prescribing and providing educational leaflets to 
patients. However, some of the week’s activities were limited due to restrictions of visits during 
the pandemic.  
Act. The PDSA’s framework final stage determined if modifications were needed before 
the last cycle based on what was learned from the previous cycles. The cycles provide iterative 
testing to improve or change the QI project. This process is evaluated on a continuum to assess 
the effectiveness of interventions used and modified during the cycles. 
The proposed Doctor of Nursing Practice (DNP) project aimed to implement an 
algorithm through the collaborative effort of providers within the clinic. The clinic project team 
members were assigned to specific tasks with educating patients. The goal was to identify all 
individuals with specified genotypes of hemoglobin SS and hemoglobin Sβ-0-thalassemia for 
hydroxyurea prescribing. In addition, the team had informal bi-weekly meetings to discuss the 
QI project addressing any questions or concerns with implementation.  
Ethical Considerations & Protection of Human Subjects  
 The project lead collaborated with the project champion at the comprehensive sickle cell 
clinic in addressing any ethical issues. The participants were treated fairly with equality, 
protecting their characteristics of race, gender, disability, religion or belief, and sexual 
orientation. Individuals were treated with dignity and respect, and their information was 
protected with privacy during this process.  
In addressing the ethical considerations, the organization required specific training 
through Collaborative Institutional Training Initiative (CITI) reviewed Group 2 
Social/Behavioral Research Investigators and Key Personnel. These were completed in 
preparation for the formal approval process (CITI, 2017). CITI is required for all persons 
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involved with human subjects and identifiable data to be used in the QI project or research. All 
efforts were made to ensure respect for dignity, anonymity, do no harm, and confidentiality 
maintained. This activity is part of the university requirement prior to the submission of 
document necessary for the Institutional Board Review (IRB). 
Institutional Review Board Approval  
A clear definition of the scope of the problem was identified and submitted to the 
Nursing Research Council for approval at the institution. A letter of organizational support was 
obtained from the project’s site. The IRB of the academic center reviewed the QI project and 
deemed the project as non-human subject research. In addition, the university quality IRB review 
process was also completed, with no further formal IRB review required. However, there was 
additional training necessary to protect the subjects from Health Insurance Portability and 
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Section III. Project Design 
Project Site and Population  
 The quality improvement project was conducted in an Adult Comprehensive Sickle Cell 
Clinic. The project lead collaborated with the project site champion at the academic setting 
affiliated with a nonprofit healthcare system in central North Carolina. The project aimed to 
implement an algorithm for standardizing Hydroxyurea (HU) at the clinic. The clinic serves 
approximately 450 individuals with various genotypes [Associate Professor] of Adult 
Comprehensive Sickle Cell Clinic personal communicator, July 17, 2020). The population for 
the project comprised of individuals with specific genotypes, particularly hemoglobin SS and 
hemoglobin Sβ-0-thalassemia. Patients traveled from various surrounding counties, mainly from 
rural areas, for the hematological expertise care, which transportation can present as a barrier for 
many.  
Description of the Setting 
  The setting for this DNP project is the Adult Comprehensive Sickle Cell Clinic, a 
hospital-based outpatient clinic located in central North Carolina. The hematologists at this clinic 
are skilled and equipped to diagnose and treat various sickle cell disease genotypes. The patient 
population is virtually African Americans. SCD occurs worldwide but is more prevalent in 
African Americans (Keikhaei et al., 2015). Sixty percent of patients at the clinic are either 
insured by Medicaid or Medicare or other individuals by private insurances [ Project Champion] 
personal communicator, August 17, 2020). 
Clinicians of the practice consist of three nurse practitioners, four medical doctors, five 
nurses, medical office assistants, triage nurses, office clerical staff members, clinical social 
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workers, clinical educators, psychiatrists, and other multidisciplinary teams that provide 
excellent care for patients with SCD. The clinics operating hours are Mondays through Fridays 
from 8 am to 5 pm, with most clinicians seeing patients with SCD and other hemoglobinopathies 
two to three times weekly. In addition, hematologists are available to provide 24 hours on-call, 
including weekdays, weekends, and holidays.  
Description of the Population   
 The clinic staff consisting of three physicians, one advanced practice practitioner (APP), 
and the four clinical nurses will be the target group for the project. All who currently work full-
time in the clinic. The project team leader will educate the providers, clinical research specialists, 
and the nurses. In addition, the clinical staff nurses, clinical research specialists, and providers 
will inform the patients about hydroxyurea. The clinic sees approximately 30-40 patients weekly, 
with most patients being seen every three months during their interval follow-up appointments.  
 The population of patients served at the clinic includes adults aged 18 years and older of 
various genders. The population comprises of patients with SCD, mainly genotypes, hemoglobin 
SS and hemoglobin Sβ-0-thalassemia. The characteristic of SCD is characterized by “chronic 
anemia, painful crisis, organ damage, reduced quality of life, high health care costs, and 
shortened life span” (Smaldone et al., 2016, p.1). Compared to healthy individuals, patients with 
SCD experienced significant declines in their quality of life across their lifespan due to the 
disease’s complications (Keikhaei et al., 2015). The population consists 50% of hematological 
etiologies in the practice of the specified genotypes being evaluated [Project Champion] personal 
communicator, August 17, 2020).  
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Project Team 
 The project team consisted of the project leader (Doctor of Nursing Practice (DNP) 
student), project champion, faculty mentor, nurses, clinical research specialist, and 
administrative staff. The project leader’s role in collaboration with the project champion 
included planning, implementing, and evaluating the project. The project champion was 
instrumental in guiding the plans carried out by the project leader. The faculty mentor also 
provided guidance and feedback during the monthly project update meetings on the 
implementation and process. 
The nurses and clinical research specialists played an active role in educating the patients 
about HU. The administrative staff checked in the patients and made return appointments. In 
addition, the project lead worked closely in collaboration with the clinical research specialist 
with uploading HU videos, HU educational pamphlets, and importing data in REDCap. 
Education was provided in the English language, using Apple iPads for reviewing HU videos 
and leaflets on HU. In addition, the nurses collected questionnaires on HU after the visits and 
educated the patients on downloading the websites for the YouTube video sharing on their 
smartphones or computers.  
Project Goals and Outcome Measures  
 The DNP project goal was to identify the prescribing practices of providers with using 
the algorithm for standardizing HU. The quality improvement project evaluated whether 
providing clinicians an algorithm and the patients with educational leaflets increased the 
prescriptions for HU amongst the physicians and APP caring for SCD patients of specific 
genotypes. The project was evaluated over 12 weeks, using the algorithm initiative to improve 
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HU prescribing by the physicians and APP. The project’s measurable outcome was to increase 
HU prescribing to at least 80%. The outcomes were obtained by evaluating the weekly 
prescribing of hydroxyurea.  
Description of the Methods and Measurements  
The Plan-Do-Study-Act (PDSA) cycles were chosen to implement the DNP quality 
improvement (QI) project. The project was designed to promote provider HU prescribing based 
on evidence-based practice guidelines for standardizing HU. Providers used an algorithm 
adapted from Up to Date and evidence-based guidelines from the National Heart Lung and Blood 
Institute (NHLBI) addressing sickle cell patients with hemoglobin SS and hemoglobin Sβ-0-
thalassemia. In addition, the algorithm provided recommendations for providers to address other 
genotypes based on their complications and disease severity.  
 PDSA cycles allowed the opportunity to test change and observe the plan by collecting 
and reviewing of specific data. The project consisted of three cycle reviews at one month, two 
months, and three months. Run charts were used to visualize weekly HU percentages of all the 
providers (see Appendix E). An excel spreadsheet was used to collect provider education and 
prescriptions for hydroxyurea with providers identified as A, B, or C (see Appendix F). A 
questionnaire was obtained from the patients at the conclusion of their visit. (see Appendix G). 
The summary from the questionnaire provided feedback that included: demographics, HU 
education, and HU prescribing (see Appendix H). 
Discussion of the Data Collection Process 
  Data analysis from the project was collected from vital documents: Maestro Care 
snapshots, physician’s and APPs notes, clinical records, medication administration records 
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(MAR), and questionnaires. In addition, the project team lead in collaboration with the clinical 
research specialists met weekly with a combination of in-person and virtual visits to review 
patients’ charts using the Maestro Care snapshot. The activities provided an overview/summary 
of the patients’ profiles. The sections identified the patients with hemoglobin SS and hemoglobin 
Sβ-0-thalassemia.  
The clinical records provided practical information that identified the practicing provider 
of the eligible patients. The MARs were reviewed to determine if the patients were currently 
prescribed HU. The project lead reviewed the initiation of HU of the providers during the clinical 
visit and documented the findings on the excel spreadsheet. The patients completed the 
questionnaire while in the clinic, with the team members importing the data into the Research 
Electronic Data Capture (REDCap). REDCap is a web-based application that supports data 
capture for research studies (Kragelund et al., 2018). The research specialist, in collaboration 
with the project lead, built the data sets in REDCap. The software was supported by the 
organization and was used to evaluate the feedback from the surveys. The software provided 
descriptive data related to the participant’s demographic characteristics of gender, genotype, 
general SCD questions related to laboratory assays, education, and hydroxyurea prescriptions.  
The outcome measures included data collected weekly by the project lead in 
collaboration with the clinical research specialist. In addition, the project included weekly chart 
reviews at the start of implementation and throughout the 12 weeks. The project team lead 
entered the data from the spreadsheets weekly. The tools were used to evaluate the prescriber 
encounters for patients who met specific criteria for HU education and HU prescribing on 
specified days as identified by Provider A, B, and C. A run chart was used to display the weekly 
percentages for HU prescribing of the clinicians.  
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Implementation Plan 
 The implementation phase of this project, began with the project team lead collaborating 
with the project champion and meeting with the providers, clinical research specialist, and the 
team members to provide an overview of the project (see Appendix I). The project lead reviewed 
the algorithm with the providers and offered educational leaflets on hydroxyurea. Additionally, 
the team reviewed the videos and educational modules on HU. The project team leader met 
weekly or bi-weekly with the project champion and weekly with the project team members. 
Furthermore, the project leader met with the team members to address any questions or concerns 
about HU or the project goals.  
During implementation, the staff provided the participants with HU pamphlets, 
questionnaires, and iPad to review videos on HU. PDSA cycle reviews were conducted monthly 
by the project lead in collaboration with the project champion. The chart reviews were conducted 
using the snapshot and the providers’ clinical notes for identifying eligible patients. The data was 
reviewed weekly on eligible patients for HU, prescriptions for HU, and education provided on 
HU. This process included importing the data into the Microsoft Excel spreadsheets for data 
analysis and creating run charts to trend weekly prescribing that reflected the improvement that 
took place over a period of time.  
Furthermore, based on the weekly reviews and informal weekly meetings with the project 
team, barriers to the project were addressed for HU prescribing and education by providing 
constructive feedback.  A new PDSA cycle was started each month to evaluate and set priorities 
for small change. There was a total of three cycles at the conclusion of the implementation phase. 
At the conclusion of the three PDSA cycles, data were analyzed from the excel spreadsheets and 
ALGORITHM FOR HYDROXYUREA                                                                                       25 
 
displayed in run charts. The data will be presented using both the excel spreadsheet and run chart 
for identifying hydroxyurea prescribing of the providers. 
Timeline  
 The project implementation occurred over three months (see Appendix I). The initiation 
of the DNP project began in November 2020 with the initial submission of the Nursing 
Research/Project Organizational Feasibility form along with the project summary submitted to 
the healthcare organization. The proposed project was submitted in November 2020 to the 
Institutional Review Board (IRB), and the organization deemed the project a QI initiative process 
development project. The project’s planning was implemented on February 1, 2021 and 
concluded on April 23, 2021.  
There were weekly run charts plotting the progression of HU prescribing and education 
provided by the clinicians for the participants. In addition, the excel spreadsheet were used to 
track the daily prescribing and weekly percentages of the providers. The monthly reviews 
marked the start of a new PDSA cycle with subsequent cycles of 2 and 3. The completed final 
data analysis of the project was in May 2021. Data analysis retrieved from the flow chart and 
excel spreadsheets reflected results over the 12 weeks and a review of the three PDSA cycles of 
the project. Dissemination of the project findings to the project site occurred on July 13, 2021. 
The project was formally closed with a poster presentation at the College of Nursing and the 
DNP paper submitted into the ScholarShip repository in July 2021.  
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Section IV. Results and Findings  
 The project’s primary goal was to improve Hydroxyurea (HU) prescribing of the 
providers for eligible participants with hemoglobin SS and hemoglobin Sβ-0-thalassemia. 
Implementation included using an evidence-based algorithm for providers and educational 
leaflets to improve HU prescribing of the clinicians. The process was measured by tracking HU 
prescribing and education by providers using a tabulated Excel spreadsheet and run charts.  
Results  
One hundred and one (101) eligible patients met the criteria for adults 18 years of age and 
older, with sickle cell disease (SCD) genotypes hemoglobin SS or hemoglobin Sβ-0-thalassemia 
as determined by hemoglobin electrophoresis and snapshots in Maestro Care. Of the 101 patients 
seen, all 101 (100%) received educational handouts and videos sharing links, and 81 (80%) were 
prescribed hydroxyurea. The algorithm provided a quick reference for the providers to identify 
the patients assigned to specific genotypes. The providers met the benchmark of 80% HU 
prescribing, except for weeks that accounted for providers on vacations, hospital rounding, and 
limited in-person visits in response to the COVID-19 pandemic.  
 During the 12-week implementation period, 20 individuals were not prescribed HU. Of 
the 20, five (25%) were pregnant. In the second trimester, the therapy can be safely given based 
on the hematologist’s preference and depending on the patients’ disease severity [Professor of 
Obstetrics & Gynecology], personal communication, February 21, 2021). Therefore, the 
individuals declined the therapy with consideration of restarting hydroxyurea once they 
delivered. Seven (35%) of the 20 declined additional disease-modifying treatments. The 
remaining eight (40%) of the 20 were treated via chronic blood transfusions or red blood cell 
exchanges, an alternative disease-modifying therapy. Generally, in the setting of chronic blood 
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transfusions or red blood exchanges, HU is normally not clinically indicated since the patients 
are already receiving a disease-modifying therapy that would increase their hemoglobin 
[Associate Professor of Adult Comprehensive Sickle Cell Clinic] personal communication, 
February 1, 2021. Treatments involve receiving blood products to improve the patient’s 
hemoglobin are often individualized by the provider’s preferences for preventing the severity of 
their disease and alleviating additional irreversible complications of sickle cell disease.  
 Data were extracted weekly from the Microsoft Excel spreadsheet, which included 
weekly prescribing of the providers and the number of eligible patients at the adult 
comprehensive sickle cell clinic. There were 59 (58%) females and 42 (42%) males who met the 
criteria (see details in Appendix H). Of the 101 eligible patients, 80% were prescribed HU, and 
20% did not receive the medication.  
The results were examined during three PDSA reviews: Weeks 1-4, Weeks 5-8, and 
Weeks 9-12. During weeks 1-4, 30 (85%) out of 35 patients were prescribed HU and provided 
educational leaflets. In weeks 5-8, 28 (76%) out of 37 patients were prescribed HU and provided 
education. In the final weeks 9-12, 23 (79%) out of 29 patients received HU prescriptions and 
education.  
In weeks 5-8 (76%) of patients were prescribed HU, and the prescribing ranged from 
60%-100%. The goal of 80% HU prescribing was not met during weeks 7-9. It was noted during 
this time, several providers were either on vacations or hospital rounding, which could have 
contributed to the decline in HU prescribing (see Appendix E and F).  
During weeks 9-12, 23 (79%) out of 29 patients were prescribed hydroxyurea, ranging 
from 50% to 81% prescribing by providers (see Appendix E and F). A decrease in patients seen 
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was noted with limited provider availability due to hospital rounding and vacations. Data 
analysis was for weekly prescribing of all providers instead of individualized prescribing.  
Using the PDSA review process, changes were implemented based on the staff and 
project champions’ input related to weekly prescribing of all providers during cycle one. 
Furthermore, changes to the subsequent cycles (Cycles 2 and 3) included using smart phrase 
links for providing education based on feedback from the project lead, clinical research 
specialists, and project team members at the conclusion of the visits. The smart phrase links 
provided sharing of literature from the links readily available to the patients using technological 
resources.   
Discussion of Major Findings  
During the project’s implementation phase, 101 patients met the inclusion criteria, 101 
were educated, and 81 received prescriptions. This project achieved the original goal 80% 
hydroxyurea prescribing during the implementation phase, with 9 out of 12 weeks meeting the 
goal. Although the percentages decreased during weeks 7, 8, and 9; the clinicians met the overall 
goal of 80%. Prior to implementing the project, providers were prescribing hydroxyurea at 60%. 
Findings from the data analysis supported the intended outcomes of meeting the benchmark of 
80% of hydroxyurea prescribing using the algorithm and providing education on HU. This was 
an improvement from 60% in HU prescribing prior to implementation 
The COVID-19 pandemic has significantly impacted hydroxyurea prescribing and 
educational opportunities for the providers. While it may have been challenging, the pandemic 
affected the outcome through social distancing requirements, reduced office visits and impacted 
educational opportunities for the providers. Before the pandemic, the providers’ weekly panels 
included at least 12 or more potential patients who were seen and eligible for HU. During the 
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project implementation, often visits were conducted by telemedicine that included telephone or 
video visits which, limited the in-person visits. Furthermore, the pandemic redirected resources 
and limited in-person visits, which may have affected the project’s intent to provide additional 
eligible individuals with educational handouts on HU. Telemedicine visits led to fewer clinic 
visits that contributed to the decrease between the expected number of patients and the actual 
number seen. 
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Section V. Interpretation and Implications 
Costs and Resource Management  
The financial costs associated with conducting the quality improvement (QI) project at 
the organization were approximately $2,670.00 (see Appendix J). Expenses related to the project 
included: educational brochures, tablets, and supplies. If the project were expanded over five 
days versus three days or involved additional providers, the cost would increase. Further costs 
associated with the project include other expenses for purchasing extra tablets, educational 
leaflets, and the costs for the 15-sheet brochures to be provided to all eligible patients. The 
administrative and advertising fees could potentially cost the organization an additional 
$3,400.00.  
The non-financial costs included the Quick response (QR) codes. QR codes were created 
online that link simple texts to websites, email, text messages, or phone calls that provide access 
to a PDF or specific application to be used on smartphones (Karia et al., 2019). QR codes 
provided a cost-effective approach for administrative expenses by using QR codes through the 
project site’s website to provide educational leaflets on hydroxyurea (HU). Additionally, the 
project lead created a link using smart phrases, also known as “dot phrases,” in the electronic 
medical record, EPIC, to send links to the patients to retrieve educational material. This would 
ideally reduce the expenditures by at least $2,200.00. This would be a cost savings by replacing 
some of the printed educational materials with visual technology. The smart phrases are links 
that were created that provided no costs to the project site’s organization.  
Each semester required a minimum of 125 hours for the project lead to plan, develop, 
implement, and disseminate the project. During this time, the project lead collaborated with the 
project champion, clinical research specialists, multidisciplinary staff, and colleagues with 
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project planning and implementation. The cost associated with the project lead time could be 
absorbed in the future by the organization through the roles of the advanced practice providers 
(APPs). The clinical nurse specialist and clinical educator who are advanced practice 
practitioners can ensure that evidence-based care for the sickle cell population will be continued 
by partnering with the organization entitled Education and Mentoring to Bring Access to Care 
(EMBRACE) network.  
The project benefits include optimizing patients with sickle cell disease in the outpatient 
setting through prescribing hydroxyurea. The cost of inpatient visits, emergency room visits, 
hospital admissions, and readmissions outweighs the cost of outpatient care. By prescribing 
hydroxyurea to eligible patients with sickle cell disease, it allows providers to optimize patient-
centered care in the outpatient setting to reduce the burdens of SCD. The medicine is effectively 
known for decreasing sickle cell pain crises, acute chest syndrome, reducing the need for blood 
transfusions, organ failure, and reduces morbidity and mortality. The annual cost related to SCD-
care expenditures can be lowered inpatient, if providers optimize hydroxyurea prescribing of the 
targeted population outpatient.  
Implications of the Findings 
 The project benefits in providing an algorithm for HU prescribing and educational 
leaflets were many. For starters, the project demonstrated an increase in prescribing by the 
providers. This initially increases the established line of communication between the patients and 
the health care team during the clinic visits. Patients were engaged by asking questions about the 
disease-modifying medication. Engaging patients in decision-making can lead to compliance 
with the identified therapy and potentially decrease irreversible complications and disease 
severity.  
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The QI project benefited the site by providing education to all the staff, including 
providers and patients on HU. The staff were provided educational leaflets and links to YouTube 
videos. The project included weekly meetings, and as a result, staff indicated that the education 
provided improved their knowledge about hydroxyurea. The providers were supported in 
prescribing hydroxyurea through the use of the algorithm.  
The project members showed a genuine interest in educating the patients about HU. 
There was an increased interest in HU after providing the patients with videos and educational 
leaflets that convey knowledge differently. The clinicians provided ongoing feedback and 
addressed concerns of uncertainty for patients during their clinic visits. The sites’ percentages for 
prescribing and providing educational leaflets was 80% or greater for 9 of the12 weeks.  
Implications for Patients 
 The project plan impacts health and wellness by educating the patients, providers, and 
ancillary staff on HU in specified genotypes; this promoted patient engagement, self-
management, and adherence to hydroxyurea. Educating patients on hydroxyurea can lead to 
reducing and preventing chronic complications of SCD. Furthermore, HU prescribing by 
providers prevented further chronic disease burdens and improved the quality of life for patients 
taking hydroxyurea. Ultimately, providing education enhances patients’ involvement with shared 
decision-making in their healthcare with engaging in self-management. Hydroxyurea prescribing 
and providing education fosters adherence to the medication regimen.  
 According to Meier (2018), hydroxyurea is well tolerated disease-modifying therapy 
effective in reducing the number of sickle cell-related complications in all ages of people with 
hemoglobin SS and hemoglobin Sβ-0-thalassemia that experience episodic moderate-severe 
painful crises. The author states, the benefits of prescribing hydroxyurea include reducing 
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neutrophils and platelet counts that ameliorate the abnormal cell adhesion-inflammation 
pathways and correct the nitric oxide deficiency associated with sickle cell and hemolysis. With 
the increasing use of this medication widespread, it is hoped to increase the survival of persons 
living with sickle cell disease.  
According to Nardo-Marino et al. (2020), HU remains the novel disease-modifying 
therapy and option in individuals with SCD. The author also notes that medication is emphasized 
as being safe and feasible in treating SCD. Of the novel therapies, HU appears to remain the only 
drug that improves the natural history of SCD (Nardo-Marino et al., 2020).  
The average cost to patients for 12 months of hydroxyurea ranges from $59.00-$110.83, 
depending on the retail pharmacy (Shah et al., 2020). Most of the patients seen in the practice 
site have insurance, including Medicaid, Medicare, or some private insurance, which covers the 
costs of hydroxyurea with little to no copay. Prescription cards can be provided to help with the 
fee for those who are self-pay or have higher copays. Patients may be eligible for patient 
assistance if they cannot afford the out-of-pocket costs. Hydroxyurea is noted to decrease the 
number and severity of acute pain crises when taking once-daily as prescribed, which the most 
frequent reason for individuals seeking emergent care. Prescribing hydroxyurea reduces painful 
crises, acute chest syndrome, acute complications, unnecessary blood transfusions, and 
hospitalizations significantly.  
Implications for Nursing Practice 
The projects demonstrated the value of educating the providers and multidisciplinary 
staff on the benefits of HU. The practice implications are associated with implementing an 
algorithm for standardizing HU evolved in optimizing care in the outpatient setting, which 
reduces the cost for inpatient care. This supports the importance for nurses to take a leadership 
role in educating patients, providers, and multidisciplinary staff on HU prescribing guidelines. 
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The project demonstrated that the essential role of using electronic medical records for 
evaluating the clinical process of documentation for HU prescribing of providers is vital in 
identifying patients who were eligible for HU prescribing. The QI project confirmed the integral 
role of interprofessional collaboration among the healthcare team was to improve the patients’ 
overall care. The project team learned that fostering interpersonal partnership with the team 
members, with the intent to educate the participants about HU, improves the overall care of the 
patients.  
The nurses have the knowledge, responsibility, and expertise to provide patient care. 
Nurses in adult comprehensive sickle cell clinics can teach the patients about hydroxyurea and its 
clinical importance for preventing complications. The clinical leadership role can be influenced 
by providers with nurses explaining the use of the algorithm for prescribing hydroxyurea. The 
clinical leadership will enhance the skills of the sickle cell champions by having them educate 
the providers and multidisciplinary staff about the disease-modifying medication.  
QI projects such as creating an HU prescribing algorithm allows advanced practice nurses 
to develop initiatives based on best practices to improve patient-centered care. The American 
Association of College of Nursing (AACN) DNP Essentials I through VIII are the fundamental 
outcomes competencies and core measures for all advanced practice roles, which are essential 
guidelines for graduates of the Doctor of Nursing (DNP) program (AACN, 2019). The DNP 
Essentials can be applied to QI initiatives in planning, implementing, and evaluating scholarly 
projects to improve health care outcomes based on evidence-based practice guidelines and 
recommendations (see Appendix K). This QI project applied best practices implementing 
evidence-based practice guidelines using an algorithm to standardize HU prescribing.   
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Impact for Healthcare Systems 
The project demonstrates the use of an algorithm for HU prescribing to individuals with 
hemoglobin SS and hemoglobin Sβ-0-thalassemia. The organization can improve its healthcare 
quality and reduce the burdens associated with sickle cell disease with prescribing hydroxyurea. 
The project demonstrated this by achieving the goal of 80% majority of the weeks for HU 
prescribing. This was evidenced by treating patients’ outpatient versus inpatient to optimize their 
care in the outpatient setting.  
 One objective of the project was aligned with the Triple Aim by focusing on improving 
the populations’ health quality and reducing costs to the healthcare system. The clinic can 
decrease the costs by optimizing care through outpatient with prescribing HU. Increased 
hydroxyurea prescribing minimizes the burden of the disease, prevents or reduces hospital 
admissions, specialist visits, and emergency department visits.  
 Providing an algorithm to standardize HU management is an effective way to improve 
the patients’ outcomes and prevent complications. The project implemented evidence-based 
practices to reduce healthcare costs by optimizing individualized care in an outpatient setting 
through prescribing HU to eligible sickle cell disease patients. This can lead to saving costs 
associated with blood transfusions. The individuals usually receive a minimum of 2 units of 
packed red blood cells which cost, $6,441.00. In addition, other patients may require red blood 
cell exchange, which costs $4,996.00 per session [Patient Financial Coordinator] personal 
communication, April 1, 2021). Therapeutic blood transfusions are provided monthly or more 
often and used to address acute events that include strokes, acute chest syndrome, and 
symptomatic anemia, which can be costly.  
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Sustainability 
The practice identified ways to continue the initiative with the current staffing model 
with the use of advanced practice providers. This will be a continuum of the advanced practice 
providers’ current roles and responsibilities. The costs associated with the staff and provider’s 
time and other resources are feasible with the current plan. This can be supported beyond the 
project implementation with modifications made to the budget associated with the costs of 
educational leaflets and tablets. Staff members were identified who remain genuinely interested 
in educating the adult population on HU. The organization would benefit from designating sickle 
cell champions at the site to provide ongoing education on hydroxyurea and an algorithm for the 
ancillary staff and providers. The cost associated with the sickle cell champion advocating for 
patients with sickle cell disease and the use of hydroxyurea is far less than the rising costs of 
emergency department visits or hospitalizations.  
A recommendation is for the project site to replace HU educational leaflets with QR 
codes using enhanced technology to support teaching and patient education, while reducing 
printed materials costs. The use of technology is a way that provides secure links for providing 
educational leaflets on HU to the patients. QR codes uses a quick response barcode to store data 
on specific topics for the user to access information instantly. This was supported by the 
Information Technological (IT) department at no additional fees to the organization.  
In addition, the project will continue the site’s established association with the 
EMBRACE sickle cell network. The relationship is built on a collaborating agreement with other 
sites and specialists interested in taking care of individuals with SCD through increased 
hydroxyurea prescribing. The site will continue to use the standardized algorithm to guide HU 
prescribing in specific genotypes. The algorithm will be incorporated into practice in rural areas 
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and specialized areas that take care of individuals with SCD. This cost-effective intervention 
educates clinicians about HU, which optimizes care for individuals with SCD.  
Dissemination Plan 
The project findings will be formally presented at the organization’s health care 
institution on July 23, 2021. The projects data findings will be presented at a staff meeting. A 
poster of the quality initiative will be printed and displayed at the site for the patients, staff, and 
community. This will provide an opportunity for the clinic’s audience to visualize the quality 
improvement initiative. This project site targets the patient population with SCD advocating for 
hydroxyurea.  
The project was presented at the University College of Nursing on July 13, 2021. The 
final DNP paper was submitted to the university ScholarShip repository for public access on July 
22, 2021. Additionally, presentations will be presented to the organization’s Nursing Research 
Council, Education and Mentoring to Bring Access to Care (EMBRACE) SCD Network, sickle 
cell champion meetings, local churches, seminars, and local and state conferences upon requests. 
In addition, virtual presentations to Extension for Community Healthcare Outcomes Project 
(ECHO), which is a group that provides virtual meetings delivering best-practice care to various 
communities addressing health care disparities. The project lead plans to submit an abstract 
before the deadline to a potential journal of interest. Journals being considered to include the 
American Journal of Hematology and The American Journal of Nursing.  
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Section VI. Conclusion 
Limitations and Facilitators 
The project’s limitations included limited time to implement a quality improvement (QI) 
project over 12 weeks with only three Plan-Do-Study-Act (PDSA) cycles in the setting during 
the COVID-19 pandemic. The coronavirus disease has affected healthcare systems globally. The 
limitations included the limited in-person visits with face-face interactions by the patients 
secondary to the COVID-19 pandemic with restrictions of social distancing. This resulted in a 
small sample size of 101 individuals who met eligibility criteria at the clinic.  
Another limitation was time spent with the patients on telephone call visits by the team 
members filling out the questionnaire on individuals who left before completing the form. There 
were several missed return calls from the patients, and it was challenging to reach the patients. 
Often, the telephone number provided were not in service or incorrectly supplied.  
The project champion provided support to the project lead with guidance and suggestions 
making necessary changes in project planning and data collection analysis. The collaborating 
partnerships with project members and administrative support were the significant facilitators of 
the project in implementing changes during challenges related to the pandemic. The primary 
team members included the project champion and research specialists, whose genuine interest in 
collaboration made a tremendous impact on the project’s success. The team members and 
clinical research specialists’ support helped with gathering the pertinent data for the project. 
With available technology, the project lead was creative in creating smart phrases that provided 
links for patients to review HU literature during clinic visits and uploaded to the after-visit 
summaries. The project lead and team members were open to using smart phrases and created a 
website for the QR codes that provided patients with educational leaflets on HU.  
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Recommendations for Others  
The current DNP project would be beneficial and should be replicated in medical settings 
that include primary care, family practice, or internal medicine practices. Standardizing the 
prescribing of HU based on evidence practice guidelines can impact patient outcomes in a 
practice setting serving the sickle cell population. The algorithm included starting at 15-20 
mg/kg dosing and titrating to the patients’ maximized tolerated dose. Often, this medication is 
primarily prescribed by hematology specialists but can be prescribed by others with the support 
of the algorithm. With the help of a hematologist or authorized prescriber, this project could 
benefit the clinicians in rural areas and even globally by optimizing the care of individuals with 
SCD. The project lead recommends providing continuing education courses to health care 
professionals in primary care, family medicine, internal medicine, multidisciplinary staff, and 
rural areas about HU that include quarterly and annual updates.  
 A recommendation is for the algorithm be placed electronically in medical records as a 
guide to be used by inpatient providers for prescribing hydroxyurea. The algorithm guides the 
initial step in providing hydroxyurea to reduce the complications and severity of the disease. In 
addition, to build on the project by incorporating educational material electronically in the 
patient’s portal for easier access to HU literature. This will help with initiating hydroxyurea and 
increase the interest of patients while being hospitalized or in outpatient settings.  
Recommendations for Further Study 
 This DNP project could be replicated by providing additional evidence-based studies that 
address adherence to hydroxyurea. Additionally, studies assessing and evaluating providers’ 
behaviors in optimizing hydroxyurea to reach the maximum tolerated dose in individuals. Future 
studies could provide updates on the current clinical benefits of HU since the last updated literature 
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from the National Heart, Lung, and Blood Institute (NHLBI) evidence-based guidelines were 
published in 2014 (Ware, 2015). In addition, clinical trials evaluating the success of HU 
prescribing in other countries and strategies for improving adherence in individuals globally are 
needed. 
 It would be beneficial to know if providing an algorithm to standardize HU in practices 
would increase the prescribing of clinicians locally and nationally. Due to the clinical benefits 
associated with hydroxyurea therapy, additional studies are needed to emphasize the benefits of 
the medication. Further studies are recommended on how the limited visits during the pandemic 
impacted HU prescribing and education provided to the patients. Since the COVID-19 pandemic 
started almost a year ago before the project implementation, it seems unlikely that COVID-19 not 
only affected prescribing for several weeks, but also the number of office visits. 
Final Thoughts 
The project started with the prediction of prescribing hydroxyurea to achieve the goal of 
80%. Educational session for the team members were adjacent to providing an algorithm to the 
providers, which enhanced their knowledge about hydroxyurea. Data analysis was collected on 
specific genotypes hemoglobin SS and hemoglobin Sβ-0-thalassemia throughout the 
implementation, which identified providers achieved the goal of 80% hydroxyurea prescribing 
from pre-implementation of 60%. Continuing this initiative offers partnerships with other 
clinicians such as the EMBRACE network for increasing the awareness of hydroxyurea 
prescribing for patients with SCD. The project team members have enhanced the patient’s 
education and knowledge about HU by promoting self-management with implementing the 
project. The project provides a foundation for improving care in patients with sickle cell disease. 
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The project aligned with the Triple Aim, by providing a medication that reduces capital costs, 
provides patient-centered care, and reduces the economic burdens of the disease.  
  
ALGORITHM FOR HYDROXYUREA                                                                                       42 
 
References 
American Association of Colleges of Nursing (AACN). (2019). AACN Essentials. 
https://www.aacnnursing.org/Portals/42/Publications/DNPEssentials.pdf  
American Society of Hematology (2020) Hydroxyurea for sickle cell disease treatment 
information. www.hematology.org.scd 
Badawy, S. M., Cronin, R. M., Hankins, J., Crosby, L., DeBaun, M., & Thompson, A. A. (2018). 
Patient-Centered ehealth interventions for children, adolescents, and adults with sickle 
cell disease: Systemic Review. Journal of Medical Internet Research. 20(7), e10940. 
https://doi.org/10.2196/10940 
Badawy, S. M., Thompson, A.A., Lai, J. S., Penedo, F. J., Rychlik, K., & Lien, R. I. (2017).  
 Adherence to hydroxyurea, health-related quality life domains, and patients’ perceptions 
of sickle cell disease and hydroxyurea: A cross-sectional study in adolescents and young 
adults. Health and Quality of Life Outcomes, 15(1), 136.  
https://doi.org/10.1186/s12955-017-0713-x 
Bakshi, N., Sinha, C. B., Ross, D., Khemani, K., Loewenstein, G., & Krishnamurti, L. (2017). 
Proponent or collaboration: Physician perspective and approaches to disease modifying 
therapies in sickle cell disease. Plos one, 12(7), e0178413.  
 https://doi.org/10.1371/journal.pone.0178413 
Evidence-Based Management of Sickle Cell Disease: Expert Panel Report. (2014). National 




ALGORITHM FOR HYDROXYUREA                                                                                       43 
 
Green, N.S., Manwani, D., Matos, S., Hicks, A., Soto, L., Castillo, Y., Ireland, K., Stennett, Y., 
Findley, S., Jia, H., & Smaldone, A. (2017). Randomized feasibility trail to improve 
hydroxyurea adherence in youth ages 10-18 years through community health workers: 
The habit study. Pediatric Blood & Cancer, 64(12), 1-9. 
https://doi.org/10.1002/pbc.26689 
Hankins, J. S., Shah, N., DiMartino, L., Brambilla, D., Fernandez, M. E., Gibson, R. W., 
Gordeuk, V. R., Lottenberg, R., Kutlar, A., Melvin, C., Simon, J., Wun, T., Treadwell, 
M., Calhoun, C., Baumann, A., Potter, M. B., Klesges, L., Bosworth, H., & Sickle Cell 
Disease Implementation Consortium (2020). Integration of mobile health into sickle cell 
disease care to increase Hydroxyurea utilization: Protocol for an efficacy and 
implementation study. JMIR research protocols, 9(7), e16319.  
 https://doi.org/10.2196/16319  
Karia, C.T., Hughes, A., & Carr, S. (2019). Uses of quick response codes in healthcare: A 
scoping review. BMC Medical Education, 19(1), 456. https://doi.org/10.1186/s12909-
019-1876-4 
Keikhaei, B., Yousef, H., & Bahadoram, M., (2015). Hydroxyurea: Clinical and hematological  
 effects in patients with sickle cell anemia. Global Journal of Health Sciences, 8(3), 252- 
 256. https://doi.org/10.5539/gjhs.v8n3p252 
Kragelund, S. H., Kjaersgaard, M., Jensen-Fangel, S., Leth, R. A., & Ank, N. (2018). Research 
Electronic Data Capture (REDCap) used as an audit tool with a built-in database. Journal 
of Biomedical Informatics, 81, 112-118. https://doi.org/10.1016/j-jbi.2018.04.005 
Knudsen, S. V., Laursen, H., Johnsen, S. P., Bartels, P.D., Ehlers, L, H., & Mainz, J. (2019).  
ALGORITHM FOR HYDROXYUREA                                                                                       44 
 
 Can quality improvement improve the quality of care? A systematic review of reported 
effects and methodological rigor in plan-do-study-act projects. BMC Health Services  
 Research, 19(1), 683. https://doi.org/10.1186/s12913-019-4482-6 
Luzatto, L, & Makani, J. (2019). Hydroxyurea-An essential medicine for sickle cell disease in 
Africa. The New England Journal of Medicine. 380(2), 187-189. 
https://doi.org/10.1056/NEJMe1814706 
Meier, E.R. (2018). Treatment options for sickle cell disease. Pediatric Clinic of North America, 
65(3), 427-443. https://doi.org/10.1016/j.pcl.2018.01.005 
Melnyk, B. M., & Fineout-Overholt, E. (2019). Evidenced-based practice in nursing & 
healthcare: A guide to best practice (4th ed.). Philadelphia: PA. Wolters Kluwer 
 ISBN-13:978-1496384539 
Nardo-Marino, A., Brouse, V., & Rees, D. (2020). Emerging therapies in sickle cell disease. 
British Journal of Haematology, 190(2), 149-172. https://doi.org/10.1111/bjh.16504 
Nazon, C., Sabo, A.N., Becker, G., Lessinger, J. M., Kemmel V., & Paillard, C. (2019).  
 Optimizing hydroxyurea treatment for sickle cell patients: The pharmacokinetic 
approach. Journal of Clinical Medicine, 8(10), 1-10. https://doi.org/10.3390/jcm8101701 
Office of Disease Prevention and Health Promotion. (2015). Increase the proportion of persons 
 with hemoglobinopathies who receive disease-modifying therapies. Healthy People 2020.  
 U.S. Department of Health and Human Services. https://healthypeople.gov/2020/topics- 
 objectives/topic/blood-disorders-and-blood-safety/objectives 
Office of Disease and Health Prevention. (2018). Development of the national health and disease 
ALGORITHM FOR HYDROXYUREA                                                                                       45 
 
prevention objectives for 2030. U. S. Department of Health and Human Services. 
https://www.healthypeople.gov/2020/About-Healthy-People/Development-Healthy-
People-2030 
Prochaska, J.O., & Velicer, W.F. (1997). The transtheoretical model of health behavior change.  
 American Journal of Health Promotion: AJHP, 12(1), 38-48.  
 https://doi.org/10.4278/0890-1171-12.1.38 
Raihan, N. & Cogburn, M. (2020). Stages of change of theory. April 5. In: Statpearls [Internet].  
 Treasure Island (FL): Statpearls Publishing; 2020 January. PMID: 32310465. 
Shah, N., Bhor, M., Xie, L., Paulose, J., & Yuce, H. (2020). Medical resource use and costs of 
treating sickle-cell related vaso-occlusive crisis episodes: A retrospective claims study. 
Journal of Health Economics and Outcomes Research , 7(1), 52-60. 
https://doi.org/10.36469/jheor.2020.12852 
Smaldone, A., Findley, S., Bakken, S., Matiz, L. A., Rosenthal, S. L., Jia, H., Matos, S.,  
 Manwani, D., & Green, N. S. (2016). Study protocol for a randomized controlled trial to 
 assess the feasibility of an open label intervention to improve hydroxyurea adherence in 
 youth with sickle cell disease. Contemporary Clinical Trials, 49, 134-142.  
 https://doi:10.1016/j.cct.2016.06.004 
Smith A. W., Bodas, P., Sidebotham, L., Weilnau, J., & Wildman, B. (2019). Improving uptake 
of hydroxyurea in patients with sickle cell disease: A retrospective study of a clinic-based 
change in consenting practices. Journal of the National Medical Association, 111(2), 
169-175.  
Strouse, J. J. (2016). Hydroxyurea for sickle cell disease: Now is the time! Southern Medical 
Journal, 109(9), 535-537. https://doi.org/10.14423/SMJ.0000000000000515 
ALGORITHM FOR HYDROXYUREA                                                                                       46 
 
Swarthout, M., & Bishop, M. A. (2017). Population health management: Review of concepts and 
definitions. American Journal of Health-Systems Pharmacology, 74(18), 1405-
1411.https://doi.org/10.2146/ajhp170025 
The CITI Program. 2017. “Webpage Title.” Accessed August 26. 
https://www.citiprogram.org/index.cfm?pageID=260 
U.S. Department of Health & Human Services. (2016, February 16). Human subject regulations  
 decisions charts: Pre-2018 requirements.  
http:www.hhs.gov.ohrp/regulations-and-policy/decision-charts-pre-2018/index.html#c4 
U.S. Department of Health & Human Services. (2018, August). Protection of Human Subjects in  
 Research. https://www.ahrq.gov/funding/process/grant-app-basis/hsubjects.html 
Ware, R. E. (2015). Optimizing hydroxyurea therapy for sickle cell anemia. American Society of  





ALGORITHM FOR HYDROXYUREA                                                                                       47 
 
Appendix A 
Search Log  
Date of 
Search 
Database  Key Word 
Searches  







articles as well as 
for inclusion) 
7/18/2020 CINHAL Sickle cell 



















related to adult 
populations with 
sickle cell disease 
excluded articles for 
pediatric 
populations 
7/19/2020 PubMed  Sickle cell 

















related to adult 
populations with 
sickle cell disease, 

























related opinions  
  









Level of Evidence 
IV DV or Themes 
concepts and 
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A.A., Lia,  
J.S.,  
Penedo, F.  
J., Rychlik, 
K., & Liem.  
R. L.  
2017 Adherence to 
hydroxyurea, health 
related quality of life 
domains, and patients' 
perceptions of sickle 
cell disease and 
hydroxyurea: A cross-
sectional study in 
adolescents and young 
adults 
Journal of  
Health and  







in education  




Sickle cell disease, 
Hydroxyurea, 
adherence, Health 
related quality of 




The authors suggested that assessment patients 
adherence and perceptions of Hydroxyurea (HU) should 
be assessed using other interventions. This would allow 
the clinicians to answers questions in regards to 
adherence or non-adherence.  Approaches that included 
web or mobile based platforms would provide frequent 
assessments for address individuals’ adherence in various 
settings. 
Limitations: The limitations included: the study being a 
single institution with convenience samples of patients 
with sickle cell disease (SCD), which could potentially 
limit the results, the cross sectional study limited the 
authors’ ability to examine change amongst the 
perceptions of the patients and lastly, the limitation of 
specific ages 12-22. 
Usefulness: The study identified the strategies for 
influencing HU adherence in pediatric and adults patients 
with SCD perceptions about HU.  
Synthesis: The cohort found the patients with more SCD 
complications had more utilizations of ED and hospita l 
visits their perceptions for HU was low. The patients with 
more negative perceptions, would be the individuals with 
lower perceptions about HU. In summary, the study  
should be used in various institutions to compare and 
contrast the domain scores to see if there is clinical l 
significance with medication non-adherence and examine 










A.A., &  
Shah. N.  
2018 Patient-Centered 
eHealth interventions  
for children; 
adolescents, and adults 
with sickle cell disease: 
Systematic review 














Level I   
Systematic  
Review  
Technological tools,  
Self-management of   
patients  with Sickle 
Cell Disease  
The articles identified that eHealth included: texting,  
mobile APPs, web-based APPS, mobile directed observed 
therapy contributed all provided patient centered 
technological resources that enhanced the participants ’  
interests in their disease modifying medications. The 
strategies used and knowledge about their medications ,  
and enhanced their self-management skills in managing 
their chronic illness with sickle cell disease (SCD). This  
provided a series of multimodal interventions with 
variable options of providing eHealth for their chronic 
disease.  The systematic review identified several 
positive outcomes with using eHealth which showed 
improvement of SCD with the use of technology.  
Limitations: the search was planned and criteria was 
comprehensive but the possibility of missing additiona l 
relevant articles could not be excluded. The strongest 
available evidence was peer-reviewed, there could be a 
population bias. The study size was variable in ages, and 
the definition of adherence and preventive behaviors  
and other outcomes varied which resulted in limitations  
to the study.  
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Bakshi, N., 
Sinha, C.  




n, G., &  
Krishnamur 
ti, L. 
2017 Proponent or 
collaborative:  
Physician perspectives 
and approaches to 
disease modifying  
therapies in sickle cell 
disease 
Public  














to help  
Level  VI  
Qualitative Study  





There were two approaches to addressing the disease- 
modifying agents 1) collaborative approach (CA) the need 
to discuss options with informed decisions and 2) 
proponent approach (PA) which advocated for 
predetermined treatment plans. The PA was advocated 
by the MD as the best option used by the MD and the CA 
focused on more than one treatment option. The author 
noted that MD presented HU as an option with SCD 
patients with clinical symptomology disease with 
severity. The article suggested that patient were hesitant 
to use the HU because of its classification as 
chemotherapy drug. The article suggests that there is a 
strong correlation with trust in partnering with providers 
in decision-making. The findings were limited to 
specialization of the participants with expert opinions, It 
would be ideal to expand the study to primary care and 
internal medicine providers who are not usually experts 
of SCD.  
Bokolo. A  2020 Use of telemedicine 
and virtual care for 
remote treatment in 
response to COVID-19 














Virtual Care, and  
Remote Treatment  
Telemedicine is essential as integrated in the health care 
systems for delivery of care to patients in response to the 
COVID-19 pandemic. Telemedicine supports long 
distance medical care to patients. This entails provided 
health education to providers and patients, provider 
trainings, and meeting with multidisciplinary staff. 
Although, this provided rapid access to health care there 
is also concerns about privacy or if telemedicine meets 
the standards of care with providing physical 
examinations via technology. Having high quality 
networking may present as a barrier to many. 
Telemedicine is beneficial by providing safe and 
accessible care to patients. In summary, the study 
provided ways to guide medical practitioners in ways to 
employ virtual technology to increase any resilience in 
the future.  
 





Level of Evidence 
IV DV or Themes 
concepts and 
categories  Comments/critique of the article/methods GAPS 







adherence: a protocol  
to increase 
hydroxyurea 
adherence in patients 
with sickle cell disease  
Journal of  
Medical   
Internet  
Research 
To look at 








Level III  
Randomized  




cell disease  
The primary outcome of this study was to measure HU 
adherence. The study showed significant statistical 
outcomes with using mobile technologies as an 
intervention to improve adherence for HU. Mobile 
Directly Observed (DOT) interventions would serve as a 
way to keep the patient actively involved in self -
management with their chronic disease. The study 
demonstrated that Mobile technology is not only 
applicable for addressing adherence for SCD.  The use of 
virtual technology provides a wide range of strategies for 




D., Matos,  
S., Hicks, A,  
Soto, L.,  
Castillo, Y.,  
Ireland, K.,  
Stennett,  
2017 Randomized feasibility 
trial to improve 
hydroxyurea 
adherence in youth 
ages 10-18 years 
through community 
health care workers: 
The habit study 
Pediatric  




s to improve 
Hydroxyurea  







cell disease  
The initiative of the HABIT with the community health 
workers (CHWs) provided support through coaching and 
providing educational materials to patients with close 
follow-up to improve hydroxyurea adherence. The youth 
valued the intervention of the workers and were satisfied 
with the support provided for self-management. The 
limitations included the modest sample size and limited 
statically power that would be needed to examine the 
statistical significance. The HU doses were not 
standardized. In summary the trial demonstrated 
feasibility and acceptance of using CHWs in facilities to 
help improve HU adherence. The acceptability of the 
intervention was statistically significant within the sickle 
cell disease population.  
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Hankins, J.  













, R., Kutlar,  
A., Melvin,  
2020 Integration of mobile 
health into sickle cell 
disease care to 
increase hydroxyurea 
utilization: Protocol for 




















Level  III  
Nonrandomized ,  
Closed Cohort  
Trail  




Hydroxyurea has proven to be efficacious in treating 
sickle cell disease. The goal was to increase hydroxyurea 
utilization by providing mHealth for providers and 
patients in order to 1) improve prescribing of providers 
and 2) to use mHealth technology to provide medication 
adherence and self-efficacy among the patient, which in 
turn improves self- management skill for this chronic 
disease. The goal was to support the gap between ages 
15 and 45 years, as noted the greatest gap in delivery of 
care. The logic was to foster hydroxyurea (Hu) utilizations 
among the patients and increase the interest of the 
providers behaviors for prescribing HU.  Limitations: 
Proportion of days covered (PCD) which reflects the ideal 
setting as opposed to the use of electronic bottles, or 
video recorded dose ingestion which the author notes to 
directly observe adherence of medication administration. 
The study does not include randomized mHealth 
strategies. As noted, the study is currently participants 
and anticipate to be completed in 2021. It would be 
interesting to preclude additional findings once the study 
is completed.  
 
 
Karia, C, T., 
Hughes, A., 
& Carr, S.  
2019 Uses of quick response 
codes in healthcare 
education: A scoping 
review  
BMC Medical  
Education  
Examine the 
use of quick 
response 
codes for  
health care 
education  
Level  V Review of 
Literature  
Quick codes and  
Technology  
 QR codes in health care is notably recognized in 
delivering health care with providing educational 
opportunities by using cost-effective technology. QR 
codes provides advantages and opportunities by using 
this enhanced technology aimed to provide a wealth of 
knowledge that can be easily linked by a simple text, 
website, email, or text message. This novel strategy 
fosters a variety of visual learning that can be used in 
various healthcare settings. QR codes can increase 
engagement with medical providers, educators, and 
patients. Limitations included:  the majority of articles 
included the use of qualitative students perception 
instead of quantifiable data, which could limit the data 
analysis.  
Keikhaei,  
B., Yousef,  
H., &  
Bahadoram 
, M.  
2015 Hydroxyurea: Clinical 
and hematological 
effects in patients with 
sickle cell disease  
Global  
Journal of  










Level IV Cohort- 
Study  
Hydroxyurea and 
Sickle  Cell Disease 
and hematological 
improvement  
The results of the study showed that hydroxyurea 
decreases anemia which is one of the reasons that 
patients receive transfusions. Hydroxyurea also, reduces 
several clinical manifestations that include but not all 
inclusive, decrease pain crises or severity of the pain, 
acute chest syndrome, reduces the number of 
admissions, reduces transfusions, and the number of 
visits to the specialists. In addition, patients with SCD that 
use HU therapy have a decreased rate of transfusions. 
Some individuals were completely free of transfusions by 
using HU. There was a statistically significance with 
decreased rate of hospitalizations from 93% to 31.5%. It 
was evident that HU a once-daily medication has several 
clinical benefits for patients with SCD. Limitations: were 
identified by the small sample size of 48 individuals, short 
duration of the study from 2013-2014, that limited the 
ability to summarize the survey. In addition, 
recommendations for longer follow-up with a larger 
sample size would be needed to validate the findings 
regarding HU as the sole disease-modifying medication 
for SCD.   
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Kragelund,  





Leth, R.A., & 
Ank, N.  
2017 Research electronic 
data capture (REDCap) 
used and audit tool  
with a built-in 
database  









Level V Review of  
Literature  
Audit Tool and  
REDCap  
REDCap software meets the legality requirements for 
storing private information with security. This 
information can be shared by other researchers who 
have access to the software and authorized for sharing 
the data. This web-based software can be securely used 
by researches to protect their data sets in the future. 
Limitations: Entering data manually can create human 
error, which could alternatively been corrected by using 
visualization of the data. Additionally the time spent 
with manual data collection by the two experts in the 
cases may not be feasible due to time constraints.  
Luzatto, L.,  
& Makani,  
J. 
2019 Hydroxyurea-An 
essential medicine for 
sickle cell disease in 
Africa 
The New  
England  




for the  
management 
Level V Review of  
Literature  
Hydroxyurea for 
Sickle Cell Disease in 
Africa  
Hydroxyurea is recognized globally as the standards of  
care for individuals with sickle cell disease. If 
hydroxyurea is widely available the results of trails 
identified that all patients should receive HU. Patients 
with sickle cell disease (SCD) in Africa should have this 
medication equally available to their patient population 
to decrease the morbidity and mortality of the disease.  
Meier, R. E.  2018 Treatment options for 
sickle cell disease  
Pediatric  




is effective in 
reducing 
complication 
s of sickle cell 
disease  
Level IV Cohort  
Study 
Treatment  
Therapies and  
Sickle Cell Disease  
Therapies for sickle cell disease focuses primarily on 
prevention of HbS production and reducing the amount 
of HbS circulating in the blood stream. Hydroxyurea is 
noted for reducing complications in all ages of 
individuals with specific genotypes. Increased HbF 
prevents the sickling and hemolysis which is the main 
reason patient encounter sickle cell pain crises and 
other complications. By taking this once daily 
medication will increase the fetal hemoglobin HbF, 
which increases the life span of the red blood cell, which 
in turn can prevent complications of SCD. Transfusions 
reduces the concentration of the HbS, l-glutamine may 
be used as an option to decrease pain crises, and the 
curative option the stem cell transplantation. All of the 
therapies may have risks, but hydroxyurea is noted as a 
safe option for treating SCD.  
Nardio- 
Marino, A., 
Brouse, V., & 
Rees, D.  
2020 Emerging therapies in 
sickle cell disease  
British  









and gene  
Level  V Review of  
Literature  
Sickle Cell Disease 
and Therapies  
Emerging therapies in sickle cell disease (SCD), noted, to 
date hydroxyurea remains the novel therapy and main 
treatment for SCD. This drug is noted to have a greater 
than 30 years history and remains the primary disease-
modifying option for the disease. HU has been identified 
as reducing complications of the disease, and 
improvement of quality of life, and survival. The author 
goes on to state that the other therapies may be used 
that include: Voxelotor, curative therapies which 
include the bone marrow transplant and gene therapy 
in the last decade are all options that can be used in 
treating SCD. However, the therapies may be limited to 
individuals related its costs. Hydroxyurea remains to be 
cost-effective and affordable by many.  
  
Nazon, C.,  
Sabo, A.N.,   




V., &  
Paillard, C.  
2019 Optimizing 
hydroxyurea treatment 













in optimizing   
Level  III  
Interventional  
Trail  
Sickle Cell Disease 
and Sickle Cell 
Anemia (SCA), and 
Hydroxyurea.  
Examined the pharmacokinetic parameters of nine 
children using the PK analysis, The GC/MS was noted to 
show specificity and sensitivity that was required for the 
therapeutic follow-up on HU. 9 of the 9 children achieved 
therapeutic goal. In addition 4 of the 9 were deemed as 
being non-compliant to the treatment regimen. The use 
of laboratory parameters, pill counts, and log books 
necessitate as reliable methods for evaluating HU 
adherence. Limitations: The small sample size of 9.   
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Shah , N.,  
Bhor, M.,  
Xie, L., 
Paulose, J., 
& Yuce, H.  
2020 Medical resources use 
and costs of treating 
sickle cell disease 
related vaso-occlusive 
crisis episodes: A 
retrospective claims 
study 














Level II Economic Burdens, 
Sickle Cell Disease,  
and Vaso-occlusive 
crisis 
The burdens of SCD primarily the vaso-occlusive pain 
crisis has been the driver of health care costs. 
Vasoocclusive crises remain the hallmark of the disease 
as the author notes that attributes to the significant 
economic burdens of the disease. HU has been known for 
its clinical benefits of reducing complications of the 
disease. Limitations: The study relied on mainly 
descriptive analysis of outcomes which limits the trends 
of results from direct observations or randomized clinical 
trials. There may have been discrepancies in the study 
that captured non-sickle cell patients related to the 
coding of visits during hospitalizations of patients with > 
1 SCD diagnosis. The data set ranged from 2009-2013 and 
the current clinical complications have likely changed 
since the study. The conclusion is that additional studies 
need to explore broader populations to help clinicians 
reduce vaso-occlusive crisis and address ways for 
reducing burdens of SCD.  
Smaldone,  
A., Findley,  
S., Bakken, 
S., Matiz, L. 
A.,  
Rosenthal,  
S. L., Jia, H.,  
Matos, S.,  
Manwani,  
D., &  
Green, N.  
2016 Study protocol for a 
randomized controlled 
trial to assess of an 
open label intervention 
to improve 
hydroxyurea 
adherence in youth 
with sickle cell disease  
Contemporary 












cell disease  
Level III  
Randomized  
Control Trial  




Clinical trials support HU treatments and benefits long-
term with the safety regulations. The growing body of 
evidence showed that community health workers (CHW) 
helped with improving self-management skill of the 
individuals with this chronic disease namely sickle cell 
disease. CHWs intervention can be feasible as a proposed 
to help with hydroxyurea adherence long-term. This 
strategy can be used to reach patients in rural and other 
communities that have barriers for access to care. 
Limitations: Included the time frame limited to 6 months 
period for developing interpersonal relationships with 
the CHWs. The time frame also revealed the impact of 
being able to access the HU intervention and following up 
in with adherence. The project would benefit by having a 
larger sample size and in a multi-site setting.  
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Smith, A.,  
Bodas, P., 
Sidebotha 
m, L., &  
Weilnau, J.  
2019 Improving uptake of 
hydroxyurea in 
patients with sickle cell 
disease: A 
retrospective study of 
a clinic-based change 
in consenting practices  














Level II  
Retrospective  
Study  
Hydroxyurea and  
Consenting  
Practices  
The study identified that using an informed consent for 
hydroxyurea treatment contributed to the statistical 
significance of increasing prescriptions. This helped the 
patients with making informed decision with explaining 
any side effects of the medication. Limitations included: 
there was no way to confirm if whether persons were 
eligible for HU ever offered this medication prior to the 
study. The contributions of consenting decisions of the 
patients and families was unknown. The study was not 
conducted in a controlled research setting. This was a 
clinic-based retrospective study with no controlled 
research setting.  
Strouse, J.  
J. 
2016 Hydroxyurea for sickle 















Level V Review of  
Literature  
N/A Randomized clinical trials noted by the author, that by 
using hydroxyurea in patients with sickle cell disease, it 
reduced their admissions, acute visits for pain, and acute 
chest syndrome by 50%. The concern is providers may be 
a significant barrier for prescribing HU. The survey 
identified several barriers that included: 
Concerns of providers’ lack of knowledge about HU, 
patients’ compliance with obtaining laboratory markers 
as clinically indicated, patients’ perceptions about side 
effects, possibility of reduced fertility for males, and 
having providers that have expert knowledge about HU.  
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Ware, R. E.  2015 Optimizing 
hydroxyurea therapy 
for sickle cell anemia  
American  
Society of  
Hematology  
Discuss the 
use of HU 
therapy in 
the 
treatment of  
Level V Review of  
Literature  
Hydroxyurea  
Therapy and Sickle  
Cell Disease  
The National Heart, Lung, and Blood Institute (NHLBI) has 
issued evidence-based guidelines and recommendations 
for hydroxyurea devoted to treatment for patients with 
sickle cell disease. There is strong recommendation for 
maximizing the safety and benefits of HU. Hydroxyurea 
should be offered nationally and routinely to eligible 
patients and is considered the standard of care for 
patients with SCD.  
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ASK ME ABOUT HYDROXYUREA (HU) 
FYI: What are the Benefits of Hydroxyurea  
Hydroxyurea, also called HU is > 30 years old since 1980s: drug available in prescription only 
which is approved to treat sickle cell disease.  
What are the benefits of HU? 
 Decrease frequency, severity, and duration of painful crisis or episodic events 
of vaso-occlusive crises (HU treated in patients have ½ as many painful crises, 
with longer periods b/t crises and less hospitalizations (30% or 1 in 3 prevented 
visits with HU).  
 Prevent acute chest syndrome (ACS) and reoccurrence of ACS  
 Prevent avascular necrosis (AVN) of the hip, shoulder or other major joints  
which causes pain and the need to have joint placements.  
 Prevent organ damage and death, (prevent harm to important organs like your 
brain, heart, lungs, kidneys, and eyes, which can lead to problems of kidney 
failure or vision loss). Over a 9 year period, studies noted patients had ½ the 
chances of survival (40% lowered rate for dying).  
 Reduce need for Blood Transfusions  Prevented need for 6/10 transfusions (58% 
< transfusions needed in HU-treated patients.  
 In Summary HU may help lower your level of pain, decrease the number of 
transfusions, prevent ACS, organ damage, mortality, and keep you healthy.  
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Appendix D 
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Appendix E 
Weekly Run Chart of Hydroxyurea by Providers  
 






























Weekly Prescribing of Hydroxyurea by Providers
Goal
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Appendix F 




Education/RX for HU 
Provider B 
Education/RX for HU 
Provider C 
Education/RX for HU % 
1 2/2 (100%) 4/5 (80%) 3/3 (100%) 90% 
2 3/4 (75%) 2/2 (100%) 2/2 (100%) 88% 
3 Vacation 4/4 (100%) 2/3 (67%) 86% 
4 4/5 (80%) Vacation 4/5 (80%) 80% 
5 3/4 (75%) 2/2 (100%) 1/1 (100%) 86% 
6 3/3 (100%) Hospital Rounding 1/1 (100%) 100% 
7 5/5 (100%) 5/9 (56%) 2/2 (100%) 75% 
8 3/4 (75%) 2/4 (50%) 1/2 (50%) 60% 
9 Vacation Hospital Rounding  1/2 (50%)  50% 
10 5/5 (100%) 3/4 (75%) 1/2 (50%)  81% 
11 4/5 (80%)  Hospital Rounding   Vacation  80% 
12             4/5 (80%)  3/4 (75%)   2/2 (100%)  81% 
 





















□ 66 > 
 
2. Gender of patient:  
□ Male  
□ Female 
 
3. Identify visit type: 
□ Initial visit (new establishment) 
□ Clinic follow-up visit 
□ Hospital follow-up 
 
4. Were laboratory assays done in preparation for the visit 
□ Yes    
□ No 
If yes were they collected? 
□ On site   
□ external lab 
5. Was Hydroxyurea discussed and educational material provided  
□ Yes    
□  No  
6. Did the patient review the videos on HU? 
□ Yes   
□  No 
7. Did the patient have a prescription or receive a new prescription for Hydroxyurea (HU)? 
□ Yes   
□  No 
  If not, why not?  
□ Pt already has a valid script  
□ Contraindicated documented allergy 
□ Patient refused                                          Reason:________________ 
□ Patient deferred to next visit                  
□ Medically contraindicated (pregnant, planning pregnancy, breastfeeding, other) 
Please return to Joy E. Curry at joy.curry@duke.edu or in person 
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Appendix H 
Demographics Characteristics  
Patients Ages   
18-25 41   (41%) 
26-33 23   (23%) 
34-41 20   (20%) 
42-49 12   (12%) 
50-57 4     (4%) 
58-65 0     (0%) 
66> 1     (1%) 
Gender of Patients   
Males  42   (42%) 
Females  59   (59%) 
Type of Visits  
Initial Visits 4     (4%) 
Follow-up Visits  95   (94%) 
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Appendix I 
Implementation Timeline  
DNP 1 May/ July 2020 
(Project Proposal) 
DNP II August/ November 2020 
(Tools & Education) 
DNP III Jan/April 2021 
(Project Implementation) 
DNP Project IV May/ July 2021 
(Final Preparation)  
1. Literature Review 
2. Identification of 
Problem  
3. Identification of 
Project Partner and 
Project Team 





1. Doctor of Nursing Practice 
Proposal 
2. Institutional Review Board 
(IRB) application 
3. Letter of Support from 
Institution 
4. Proposal to Nursing 
Research Council 
5. Leaflets and Education on 
HU 
6. Provided buttons Ask Me 
About HU 
7. One pager summary to 
build case for project 
8. Project Approval granted 
 
1. Implementing begins  
2/1/2021 
2. Project Team Members 
began to educate the 
participants with specific 
genotypes, Hemoglobin 
SS and Hemoglobin Sβ-
0-thalassemia 
3. Tablets with HU Videos 
provided to patients to 
review during clinic visit 
4. Plan-Do-Study-Act 
(PDSA) summarize three 
cycles  
5. Every two weeks meet 
with Project Team and 
Project Champion by 
face-face interaction, 
emails, text messages, or 
Zoom to address 
questions or concerns in 
the interval. 
6. Data collection weekly 
on M/W/Th 
7. Evaluation of 
Implementation  
 





2. Evaluation of the 
impact of the problem 
and participants of HU 
prescribing 
3. Final Approval of the 
Faculty member of the 
final paper. 
4. Preparation for the 
poster presentation at 
ECU July 2021 
5. Presentation at ECU 
in-person or virtually 
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Appendix J  

















DNP Hydroxyurea (HU) Project's Budget Plan Quantity Projected Cost PER UNIT Projected SUBTOTAL
Administrative Expenses
Computer (Tablets) 2 $600.00 $1,200.00
Fax & Coping 100 $0.25 $25.00
Advertising
Button: Ask Me About HU 50 $1.00 $50.00
Brochures: Hydroxyurea from the Amercian 
Society of Hematology-15 Sheet Package 100 $10.00 $1,000.00
HU: Educational Leaflets 100 $1.00 $100.00
Miscellaneous
White Coat Clip Boards (Nurses) 5 $19.00 $95.00
Personalized HU Pens for Particpants 75 $2.00 $150.00
Personalized HU Pens for Staff 20 $2.50 $50.00
Total $2,670.00
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Appendix K 
Doctor of Nursing Practice Essentials  





Competency – Analyzes and uses information to 
develop practice 
Competency -Integrates knowledge from humanities and 
science into context of nursing 
Competency -Translates research to improve practice 
Competency -Integrates research, theory, and practice to 
develop new approaches toward improved practice and 
outcomes 




standardizing HU in 
specific genotypes, 
particularly 
hemoglobin SS and 
hemoglobin Sβ-0-
thalassemia. 
  Knowledge gained 
from the National, 







offering HU as the 
FDA-approval for 
greater than 30 years 
for eligible participants 
with sickle cell disease 









Competency –Develops and evaluates practice based on 
science and integrates policy and humanities 
Competency –Assumes and ensures accountability for 
quality care and patient safety 
Competency -Demonstrates critical and reflective 
thinking 
Competency -Advocates for improved quality, access, 
and cost of health care; monitors costs and budgets 
Competency -Develops and implements innovations 
incorporating principles of change 
Competency - Effectively communicates practice 
knowledge in writing and orally to improve quality 
Competency - Develops and evaluates strategies to 
manage ethical dilemmas in patient care and within 
health care delivery systems 
 
 
 The initiative with 
providing an algorithm 
to guide clinicians with 
recommendations for 
HU based on specific 
criteria that outlines 
contraindications for 
HU prescribing.  
 The PDSA was 
introduced as the 
operational framework 
with 3 cycles, 4 weeks 
each testing change 
with HU prescribing of 
providers during the 12 
weeks noting the 
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success of reaching the 








Competency - Critically analyzes literature to determine 
best practices 
Competency - Implements evaluation processes to 
measure process and patient outcomes 
Competency - Designs and implements quality 
improvement strategies to promote safety, efficiency, and 
equitable quality care for patients 
Competency - Applies knowledge to develop practice 
guidelines 
Competency - Uses informatics to identify, analyze, and 
predict best practice and patient outcomes 
Competency - Collaborate in research and disseminate 
findings 
 
 The run chart used to plot 
the weekly prescribing of 
the providers.  
 The Excel spreadsheet 
tracking tool identified 
the weekly prescribing 
with analysis of the 
percentages by the 
providers individually 
ideally, but the DNP 
project partners decided 
to identify weekly 
prescribing of Providers 
identified as A, B & C in 
the setting of the COVID-
19 pandemic. 










of Health Care 
Competency - Design/select and utilize software to 
analyze practice and consumer information systems that 
can improve the delivery & quality of care 
Competency -  Analyze and operationalize patient care 
technologies 
Competency - Evaluate technology regarding ethics, 
efficiency and accuracy 
Competency - Evaluates systems of care using health 
information technologies 
 
 An algorithm was used 
to initiate prescribing 
based on specific 
evidence-based 
guidelines adopted 
from Up-to-Date and  
National, Heart, Lung, 
and Blood Institute 
(NHLBI) 
 Educational literature 
on hydroxyurea was 
provided by face-face 
interactions, smart 
phrases, and sharing 
YouTube video links.  
 Weekly Excel 
spreadsheets identified 
HU prescribing and 
education provided to 
the eligible participants. 
 QR codes were used to 
provide healthcare 
education on the 
clinical benefits of HU.  
 




Competency- Analyzes health policy from the 
perspective of patients, nursing and other stakeholders 
 The DNP project site 
used the algorithm, and 
smart phrases with 




Competency – Provides leadership in developing and 
implementing health policy 
Competency –Influences policymakers, formally and 
informally, in local and global settings 
Competency – Educates stakeholders regarding policy 
Competency – Advocates for nursing within the policy 
arena 
Competency- Participates in policy agendas that assist 
with finance, regulation and health care delivery 
Competency – Advocates for equitable and ethical 
health care 
literature to provide 




 Additionally, a website 
was created at the site 
to provide secured 
email links for the 
patients to use QR 
codes to retrieve 
education on HU. This 
advocates for providing 
literature to optimize 
the patients 
understanding of the 
therapy and supporting 
patient-centered care.  
  This new innovation of 
technology is a new 
way for patient to 
engage in self-
management by 
learning about their 









Competency- Uses effective collaboration and 
communication to develop and implement practice, 
policy, standards of care, and scholarship 
Competency – Provide leadership to interprofessional 
care teams 
Competency – Consult intraprofessionally and 
interprofessionally to develop systems of care in complex 
settings 
 The DNP project used 
the algorithm to 
prescribe this FDA-
once daily dose that is 
recognized by national 
and international 
guidelines globally as 
standards in care for 
patients with SCD.  
 The project was led by 
the DNP student in 
collaboration with the 
project champion, 
project mentor, clinical 
specialist, and the 
project team members.  
 The collaboration with 
the team and 
interpersonal 
relationships with the 
patients addressed the 





with prescribing HU to 





Technology (IT) and 
their support with of 









Competency- Integrates epidemiology, biostatistics, and 
data to facilitate individual and population health care 
delivery 
Competency – Synthesizes information & cultural 
competency to develop & use health promotion/disease 
prevention strategies to address gaps in care 
Competency – Evaluates and implements change 
strategies of models of health care delivery to improve 
quality and address diversity 
 Health promotion 
and disease 
prevention focused 
on optimizing HU 
in individuals 
addressing the 






acute on chronic 
irreversible 
complications.  
 Literature was 





modifying therapy.  
 The providers and 
project team 
members educated 





with being an 
advocate for 
prescribing HU.  
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 The eHealth and 
technical advances 
will continue to be 












Competency- Melds diversity & cultural sensitivity to 
conduct systematic assessment of health parameters in 
varied settings 
Competency – Design, implement & evaluate nursing 
interventions to promote quality 
Competency – Develop & maintain patient relationships 
Competency –Demonstrate advanced clinical judgment 
and systematic thoughts to improve patient outcomes 
Competency – Mentor and support fellow nurses 
Competency- Provide support for individuals and 
systems experiencing change and transitions 
Competency –Use systems analysis to evaluate practice 
efficiency, care delivery, fiscal responsibility, ethical 
responsibility, and quality outcomes measures 
 
 The DNP project 
Quality Improvement 




that was guided by 
evidence-based 
practice, an Excel 
spreadsheet and run 
chart identified to 
evaluate gaps and 
weekly progress in 
prescribing.  
 The participants were 
protected and embraced 
based on their culture 
preferences. 
 
 Trusting relationships 
were established 
between patients and 
healthcare team 
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members during the 
visits allowing 
participants to ask 
questions optimizing 
the care of SCD by 
reducing the burdens of 
ED visits, 
hospitalizations, and 
readmissions.  
 
